Brief report

Acamprosate in fragile X syndrome

Craig A. Erickson, Jennifer E. Mullett, Christopher J. McDougle

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Glutamatergic dysfunction is implicated in the pathophysiology of fragile X syndrome (FXS). We report on the first trial of acamprosate, a drug with putative mGluR5 antagonism, in three adults with FXS and autism. Medical records describing open-label treatment with acamprosate in 3 patients with FXS and a comorbid diagnosis of autistic disorder were reviewed. In all three patients, acamprosate was associated with improved linguistic communication. Three patients received acamprosate over a mean 21.3 weeks of treatment. All patients showed global clinical benefit as rated with the Clinical Global Impressions-Improvement scale. Marked communication improvement was unexpected and has potential implications for the treatment of FXS, as well as idiopathic autism.

Original languageEnglish
Pages (from-to)1412-1416
Number of pages5
JournalJournal of Autism and Developmental Disorders
Volume40
Issue number11
DOIs
StatePublished - Nov 2010

Fingerprint

Fragile X Syndrome
Autistic Disorder
Communication
Linguistics
Medical Records
Therapeutics
acamprosate
Pharmaceutical Preparations

Keywords

  • Acamprosate
  • Fragile X syndrome
  • Irritability
  • Language
  • MGluR5

ASJC Scopus subject areas

  • Developmental and Educational Psychology

Cite this

Brief report : Acamprosate in fragile X syndrome. / Erickson, Craig A.; Mullett, Jennifer E.; McDougle, Christopher J.

In: Journal of Autism and Developmental Disorders, Vol. 40, No. 11, 11.2010, p. 1412-1416.

Research output: Contribution to journalArticle

Erickson, Craig A. ; Mullett, Jennifer E. ; McDougle, Christopher J. / Brief report : Acamprosate in fragile X syndrome. In: Journal of Autism and Developmental Disorders. 2010 ; Vol. 40, No. 11. pp. 1412-1416.
@article{c021704d04124e2aa6a183aa5bbc5748,
title = "Brief report: Acamprosate in fragile X syndrome",
abstract = "Glutamatergic dysfunction is implicated in the pathophysiology of fragile X syndrome (FXS). We report on the first trial of acamprosate, a drug with putative mGluR5 antagonism, in three adults with FXS and autism. Medical records describing open-label treatment with acamprosate in 3 patients with FXS and a comorbid diagnosis of autistic disorder were reviewed. In all three patients, acamprosate was associated with improved linguistic communication. Three patients received acamprosate over a mean 21.3 weeks of treatment. All patients showed global clinical benefit as rated with the Clinical Global Impressions-Improvement scale. Marked communication improvement was unexpected and has potential implications for the treatment of FXS, as well as idiopathic autism.",
keywords = "Acamprosate, Fragile X syndrome, Irritability, Language, MGluR5",
author = "Erickson, {Craig A.} and Mullett, {Jennifer E.} and McDougle, {Christopher J.}",
year = "2010",
month = "11",
doi = "10.1007/s10803-010-0988-9",
language = "English",
volume = "40",
pages = "1412--1416",
journal = "Journal of Autism and Developmental Disorders",
issn = "0162-3257",
publisher = "Springer New York",
number = "11",

}

TY - JOUR

T1 - Brief report

T2 - Acamprosate in fragile X syndrome

AU - Erickson, Craig A.

AU - Mullett, Jennifer E.

AU - McDougle, Christopher J.

PY - 2010/11

Y1 - 2010/11

N2 - Glutamatergic dysfunction is implicated in the pathophysiology of fragile X syndrome (FXS). We report on the first trial of acamprosate, a drug with putative mGluR5 antagonism, in three adults with FXS and autism. Medical records describing open-label treatment with acamprosate in 3 patients with FXS and a comorbid diagnosis of autistic disorder were reviewed. In all three patients, acamprosate was associated with improved linguistic communication. Three patients received acamprosate over a mean 21.3 weeks of treatment. All patients showed global clinical benefit as rated with the Clinical Global Impressions-Improvement scale. Marked communication improvement was unexpected and has potential implications for the treatment of FXS, as well as idiopathic autism.

AB - Glutamatergic dysfunction is implicated in the pathophysiology of fragile X syndrome (FXS). We report on the first trial of acamprosate, a drug with putative mGluR5 antagonism, in three adults with FXS and autism. Medical records describing open-label treatment with acamprosate in 3 patients with FXS and a comorbid diagnosis of autistic disorder were reviewed. In all three patients, acamprosate was associated with improved linguistic communication. Three patients received acamprosate over a mean 21.3 weeks of treatment. All patients showed global clinical benefit as rated with the Clinical Global Impressions-Improvement scale. Marked communication improvement was unexpected and has potential implications for the treatment of FXS, as well as idiopathic autism.

KW - Acamprosate

KW - Fragile X syndrome

KW - Irritability

KW - Language

KW - MGluR5

UR - http://www.scopus.com/inward/record.url?scp=78549286298&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78549286298&partnerID=8YFLogxK

U2 - 10.1007/s10803-010-0988-9

DO - 10.1007/s10803-010-0988-9

M3 - Article

VL - 40

SP - 1412

EP - 1416

JO - Journal of Autism and Developmental Disorders

JF - Journal of Autism and Developmental Disorders

SN - 0162-3257

IS - 11

ER -